Premium
Serum neuron‐specific enolase: a new tool for seizure risk monitoring after status epilepticus
Author(s) -
Hanin Aurélie,
Demeret Sophie,
Denis Jérôme Alexandre,
NguyenMichel ViHuong,
Rohaut Benjamin,
Marois Clémence,
ImbertBismut Françoise,
BonnefontRousselot Dominique,
Levy Pierre,
Navarro Vincent,
Lambrecq Virginie
Publication year - 2022
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.15154
Subject(s) - status epilepticus , enolase , electroencephalography , medicine , biomarker , epilepsy , quantitative electroencephalography , anesthesia , psychiatry , immunohistochemistry , biochemistry , chemistry
Background and purpose There is a need for accurate biomarkers to monitor electroencephalography (EEG) activity and assess seizure risk in patients with acute brain injury. Seizure recurrence may lead to cellular alterations and subsequent neurological sequelae. Whether neuron‐specific enolase (NSE) and S100‐beta (S100B), brain injury biomarkers, can reflect EEG activity and help to evaluate the seizure risk was investigated. Methods Eleven patients, admitted to an intensive care unit for refractory status epilepticus, who underwent a minimum of 3 days of continuous EEG concomitantly with daily serum NSE and S100B assays were included. At 103 days the relationships between serum NSE and S100B levels and two EEG scores able to monitor the seizure risk were investigated. Biochemical biomarker thresholds able to predict seizure recurrence were sought. Results Only NSE levels positively correlated with EEG scores. Similar temporal dynamics were observed for the time courses of EEG scores and NSE levels. NSE levels above 17 ng/ml were associated with seizure in 71% of patients. An increase of more than 15% of NSE levels was associated with seizure recurrence in 80% of patients. Conclusions Our study highlights the potential of NSE as a biomarker of EEG activity and to assess the risk of seizure recurrence.